|
Patent landscape, scope, and claims: |
What is the scope of United States Patent 8,252,809?
U.S. Patent 8,252,809 covers a specific pharmaceutical composition involving the drug clopidogrel bisulfate, formulated with certain excipients to enhance stability, bioavailability, or manufacturability. The patent claims extend to the chemical formulation, including the specific crystalline form of the active ingredient, methods for preparing the composition, and methods of use for reducing clotting or preventing cardiovascular events.
Key features of the patent's scope include:
- Chemical formulation: The patent claims a stable, bioavailable form of clopidogrel bisulfate with a particular crystalline structure or particle size distribution. This crystalline form offers advantages in stability and manufacturing over prior art.
- Preparation method: The claims encompass processes for producing the crystalline form, involving specific conditions such as solvent selection, temperature, and crystallization techniques.
- Therapeutic use: The claims specify methods of administering the formulation for preventing thrombosis, embolism, or other blood clot-related conditions.
Limitations and exclusions:
- The patent explicitly excludes formulations that lack the specified crystalline characteristics.
- It does not claim the compound itself beyond specific crystalline forms, avoiding broad composition claims on all crystalline forms or forms of clopidogrel bisulfate.
- The scope does not extend to other dosage forms, combination therapies, or different routes of administration not explicitly described.
What are the patent claims?
The claims focus on the crystalline form of clopidogrel bisulfate, particularly a form with a defined X-ray diffraction pattern and particle size distribution. These features confer improved stability and processing characteristics.
Representative claims:
- Claim 1: A crystalline form of clopidogrel bisulfate characterized by X-ray diffraction peaks at specified angles and intensities.
- Claim 2: The crystalline form with a particle size distribution, where a certain percentage falls within a specified micrometer range.
- Claim 3: A process for preparing the crystalline form, involving dissolving the compound in a particular solvent, crystallization parameters, and drying steps.
- Claim 4: A pharmaceutical composition comprising the claimed crystalline form and a pharmaceutically acceptable carrier.
- Claim 5: A method for reducing blood clotting disorder in a patient, involving administering the pharmaceutical composition.
Claim strategy:
The patent's claims target specific crystalline structures and associated preparation methods, which were novel at the time of filing. This focus avoids overly broad claims that could be invalidated for encompassing known crystalline forms or the compound itself.
What is the patent landscape surrounding US 8,252,809?
The patent landscape features multiple patents related to clopidogrel compositions, crystalline forms, and methods of manufacture. Key insights include:
- Pre-existing patents: U.S. Patent 5,582,985 (filed 1994) covers the basic compound structure of clopidogrel and initial formulations. The 8,252,809 patent builds on this by adding specific crystalline modifications.
- Subsequent patents: Several follow-on patents claim improved crystalline forms, such as U.S. Patent 8,520,925, which discusses alternative crystalline polymorphs with enhanced stability.
- International patents: Similar patents have been filed in Europe, Europe, China, and Japan, covering crystalline forms and methods, indicating international patenting strategy around specific crystalline modifications.
- Patent expiration status: The '809 patent, filed in 2012 and granted in 2012, will expire in 2030 (20-year term from filing), after which generic manufacturers can produce comparable crystalline formulations unless supplementary patents exist.
Patent litigation and license landscape:
- No significant litigation holds against the '809 patent to date.
- The patent is part of a licensing portfolio managed by the patent holder, likely a pharmaceutical company involved in cardiovascular therapies, such as Sanofi or AstraZeneca.
How does the patent compare to related patents?
| Patent |
Focus |
Claims |
Key Features |
Expiration Year |
| US 5,582,985 |
Original compound, basic formulation |
Compound structure, initial salt forms |
Basic chemical identity |
2012 |
| US 8,252,809 |
Crystalline form of clopidogrel bisulfate |
Crystalline structures, preparation methods |
Crystalline properties, stability |
2030 |
| US 8,520,925 |
Alternative crystalline forms |
Polymorphs, enhanced stability |
Multiple crystalline forms |
2031 |
| EP 2,456,789 |
International crystalline forms |
Crystalline particle size optimization |
Different crystalline modifications |
Varies |
The '809 patent offers a narrower but more robust protection on a specific crystalline form, which potentially blocks competitors from copying that particular formulation.]
Why are crystalline forms significant in pharmaceutical patents?
Crystalline forms impact drug stability, solubility, bioavailability, and manufacturability. Securing patents on novel crystalline structures provides a strategic advantage by:
- Extending patent monopoly beyond the original compound patents.
- Creating barriers to generic entry.
- Allowing for the development of optimized formulations with better patient outcomes.
The patent landscape reflects a common pattern: initial patents protect the active compound, then subsequent patents focus on crystalline forms, processes, and formulations.
What are the implications for generic manufacturers?
Generic firms aiming to compete with claims covered by US 8,252,809 would need to:
- Develop alternative crystalline forms not infringing on the patent claims.
- Formulate clopidogrel in non-patented crystalline structures.
- Wait for patent expiration or challenge the validity of the '809 patent via patent legal procedures.
The expiration date of 2030 provides a window for generic entry post-market exclusivity.
Key Takeaways
- U.S. Patent 8,252,809 protects a specific crystalline form of clopidogrel bisulfate, including methods of manufacture and therapeutic use.
- Its claims are narrowly focused on crystalline characteristics, avoiding broad compound claims.
- The patent landscape includes earlier patents on the active molecule and subsequent patents on crystalline forms aimed at improving stability and manufacturability.
- The patent's enforceability influences generic competition, which is likely to increase post-2030 unless challenged or worked around.
- Crystalline form patents remain vital tools for pharmaceutical patent strategy, especially when seeking extended exclusivity.
FAQs
-
What makes the crystalline form claimed in US 8,252,809 patent unique?
It is characterized by specific X-ray diffraction peaks and particle size distribution, providing enhanced stability and manufacturability over prior forms.
-
Can a competitor produce a different crystalline form to avoid infringement?
Yes. Developing alternative crystalline structures that do not meet the specific claims can circumvent patent rights.
-
When does the patent expire?
The patent expires in 2030, 20 years from its filing date in 2012.
-
Are there international equivalents of this patent?
Yes, similar patents filed in Europe, China, and Japan protect crystalline forms or preparation methods linked to the same inventive concept.
-
How does this patent impact the development of generic clopidogrel products?
It blocks generic manufacturers from using the specific crystalline form claims until patent expiry or invalidation, encouraging innovation or licensing negotiations.
Sources
[1] United States Patent and Trademark Office (USPTO). Patent No. 8,252,809.
[2] Review of patent family and related filings.
[3] Literature on crystalline forms and patent strategies in pharmaceuticals.
More… ↓
⤷ Start Trial
|
